Loss of inhibitor of apoptosis proteins as a determinant of polyamine analog-induced apoptosis in human melanoma cells

Oncogene

Volumn 22, Issue 32, 2003, Pages 4964-4972

  Chen, Ying ^a   Kramer, Debora L ^a   Li, Fengzhi ^a   Porter, Carl W ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; DENSPM; IAP; ML IAP; Polyamines; siRNA; Survivin

Indexed keywords

APOPTOSIS INHIBITOR; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CASPASE; CYTOCHROME C; INHIBITOR OF APOPTOSIS PROTEIN; MITOCHONDRIAL PROTEIN; N1,N11 DIETHYLNORSPERMINE; POLYAMINE; PROTEASOME INHIBITOR; RNA; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SPERMIDINE N1 ACETYLTRANSFERASE; SPERMIDINE SYNTHASE; SPERMINE N1 ACETYLTRANSFERASE; SURVIVIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; N(1),N(11) DIETHYLNORSPERMINE; N(1),N(11)-DIETHYLNORSPERMINE; PROTEIN; SPERMINE;

APOPTOSIS; ARTICLE; CATABOLISM; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; DOWNSTREAM PROCESSING; DRUG ACTIVITY; EFFECTOR CELL; ENZYME ACTIVATION; ENZYME RELEASE; HUMAN; HUMAN CELL; INHIBITION KINETICS; MELANOMA; MITOCHONDRIAL RESPIRATION; POLYAMINE SYNTHESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN SYNTHESIS INHIBITION; SURVIVAL; METABOLISM; PHYSIOLOGY;

INTRACISTERNAL A-PARTICLES;

ANTINEOPLASTIC AGENTS; APOPTOSIS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MELANOMA; POLYAMINES; PROTEINS; SPERMINE;

EID: 0043029074     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1206725     Document Type: Article

References (39)

1. Ambrosini G, Adida C and Altieri DC. (1997). Nat. Med., 3, 917-921.
2. Chen Y, Alm K, Vujcic S, Kramer DL, Kee K, Diegelman P and Porter CW (2003) Cancer Res. (In press).
3. Chen Y, Kramer DL, Diegelman P, Vujcic S and Porter CW. (2001). Cancer Res., 61, 6437-6444.
4. Chen Y, Kramer DL, Vujcic S, Jell J and Porter CW. (Submitted 2003). Mol. Pharm.
5. Chen Z, Naito M, Hori S, Mashima T, Yamori T and Tsuruo T. (1999). Biochem. Biophys. Res. Commun., 264, 847-854.
6. Creaven PJ, Perez R, Pendyala L, Meropol NJ, Loewen G, Levine E, Berghorn E and Raghavan D. (1997). Invest. New Drugs, 15, 227-234.
7. Deveraux QL, Roy N, Stennicke HR, Van Arsdale T, Zhou Q, Srinivasula SM, Alnemri ES, Salvesen GS and Reed JC. (1998). EMBO J., 17, 2215-2223.
8. Deveraux QL, Takahashi R, Salvesen GS and Reed JC. (1997). Nature, 388, 300-304.
9. Du C, Fang M, Li Y, Li L and Wang X. (2000). Cell, 102, 33-42.
10. Duckett CS, Nava VE, Gedrich RW, Clem RJ, Van Dongen JL, Gilfillan MC, Shiels H, Hardwick JM and Thompson CB. (1996). EMBO J., 15, 2685-2694.
11. Fogel-Petrovic M, Vujcic S, Miller J and Porter CW. (1996). FEBS Lett., 391, 89-94.
12. Hahm HA, Ettinger DS, Bowling K, Hoker B, Chen TL, Zabelina Y and Casero Jr RA. (2002). Clin. Cancer Res., 8, 684-690.
13. Hinds MG, Norton RS, Vaux DL and Day CL. (1999). Nat. Struct. Biol., 6, 648-651.
14. Holcik M and Korneluk RG. (2001). Nat. Rev. Mol. Cell Biol., 2, 550-556.
15. Kasof GM and Gomes BC. (2001). J. Biol. Chem., 276, 3238-3246.
16. Kramer DL, Chang BD, Chen Y, Diegelman P, Alm K, Black AR, Roninson IB and Porter CW. (2001). Cancer Res., 61, 7754-7762.
17. Kramer DL, Vujcic S, Diegelman P, Alderfer J, Miller JT, Black JD, Bergeron RJ and Porter CW. (1999). Cancer Res., 59, 1278-1286.
18. LaCasse EC, Baird S, Korneluk RG and MacKenzie AE. (1998). Oncogene, 17, 3247-3259.
19. Liston P, Roy N, Tamai K, Lefebvre C, Baird S, Cherton-Horvat G, Farahani R, McLean M, Ikeda JE, MacKenzie A and Korneluk RG. (1996). Nature, 379, 349-353.
20. Olie RA, Simoes-Wust AP, Baumann B, Leech SH, Fabbro D, Stahel RA and Zangemeister-Wittke U. (2000). Cancer Res., 60, 2805-2809.
21. Porter CW and Bergeron RJ. (1988). Adv. Enzyme Regul., 27, 57-79.
22. Porter CW, Ganis B, Libby PR and Bergeron RJ. (1991). Cancer Res., 51, 3715-3720.
23. Reed JC and Bischoff JR. (2000). Cell, 102, 545-548.
24. Rothe M, Pan MG, Henzel WJ, Ayres TM and Goeddel DV. (1995). Cell, 83, 1243-1252.
25. Salvesen GS and Duckett CS. (2002). Nat. Rev. Mol. Cell Biol., 3, 401-410.
26. Shappell NW, Miller JT, Bergeron RJ and Porter CW. (1992). Anticancer Res., 12, 1083-1089.
27. Shin S, Sung BJ, Cho YS, Kim HJ, Ha NC, Hwang JI, Chung CW, Jung YK and Oh BH. (2001). Biochemistry, 40, 1117-1123.
28. Streiff RR and Bender JF. (2001). Invest. New Drugs, 19, 29-39.
29. Suzuki A, Hayashida M, Ito T, Kawano H, Nakano T, Miura M, Akahane K and Shiraki K. (2000). Oncogene, 19, 3225-3234.
30. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T and Reed JC. (1998). Cancer Res., 58, 5315-5320.
31. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M and Tanigawa N. (2000). Clin. Cancer Res., 6, 127-134.
32. van Loo G, Saelens X, van Gurp M, MacFarlane M, Martin SJ and Vandenabeele P. (2002). Cell Death Differ., 9, 1031-1042.
33. Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, Moritz RL, Simpson RJ and Vaux DL. (2000). Cell, 102, 43-53.
34. Vucic D, Deshayes K, Ackerly H, Pisabarro MT, Kadkhodayan S, Fairbrother WJ and Dixit VM. (2002). J. Biol. Chem., 277, 12275-12279.
35. Vucic D, Stennicke HR, Pisabarro MT, Salvesen GS and Dixit VM. (2000). Curr. Biol., 10, 1359-1366.
36. Vujcic S, Diegelman P, Bacchi CJ, Kramer DL and Porter CW. (2002). Biochem. J., 367, 665-675.
37. Vujcic S, Liang P, Diegelman P, Kramer DL and Porter CW. (2003). Biochem. J., 370, 19-28.
38. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP and Wang X. (1997). Science, 275, 1129-1132.
39. Zhao J, Tenev T, Martins LM, Downward J and Lemoine NR. (2000). J. Cell Sci., 113, (Part 23) 4363-4371.